Oxyacanthine

Pharmacology & Research

Oxyacanthine is a minor bisbenzylisoquinoline (bisBIQ) alkaloid of barberry (Berberis) root bark — a co-alkaloid of the principal berberine, alongside the aporphine magnoflorine and the closely related bisBIQ tetrandrine. Barberry’s ~4% root-alkaloid fraction is berberine-dominated, and oxyacanthine has almost no isolated pharmacology of its own — thin, old literature plus a little recent in-vitro/in-silico work. Its “hook” (a vasodilator/calcium-antagonist reputation) is really the pharmacology of its bisBIQ class and its cousin tetrandrine, not something measured for oxyacanthine itself.

1. Cardiovascular / smooth-muscle

Oxyacanthine is described in the older literature as a sympatholytic/anti-epinephrine vasodilator, and cardiovascular effects (vasodilation, negative inotropy, calcium antagonism) are the defining, well-reviewed action of the bisBIQ class it belongs to ^{2Reference 22002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}.

Gap: there is no dedicated modern cardiovascular study of oxyacanthine itself — the antihypertensive/calcium-antagonist claim is class-inferred (carried by tetrandrine and bisBIQ reviews), not measured for this molecule ^{2Reference 22002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}.

2. Urease inhibition

Oxyacanthine from Berberis glaucocarpa roots was a potent urease inhibitor in vitro (IC50 ~6.35 µg/mL, ~98% inhibition, more potent than thiourea) with minimal cell cytotoxicity ^{3Reference 32018NMR, novel pharmacological and in-silico docking studies of oxyacanthine and tetrandrine: bisbenzylisoquinoline alkaloids from Berberis glaucocarpa rootsView study →} — relevant to H. pylori and urinary-tract chemistry.

Gap: a single in-vitro paper on the purified compound, with no organism/infection model and no in-vivo follow-up ^{3Reference 32018NMR, novel pharmacological and in-silico docking studies of oxyacanthine and tetrandrine: bisbenzylisoquinoline alkaloids from Berberis glaucocarpa rootsView study →}.

3. Anti-inflammatory

Oxyacanthine from Berberis vulgaris root was active in carrageenan/zymosan paw-oedema, adjuvant arthritis and complement assays — but consistently less effective than berberine ^{4Reference 41996Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloidsView study →}.

Gap: subordinate to berberine throughout, with no isolated-compound clinical relevance ^{4Reference 41996Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloidsView study →}.

4. Anticancer / antiviral (in-silico)

Oxyacanthine was flagged as a high-affinity SARS-CoV-2 main-protease binder in a pure in-silico screen ^{5Reference 52021Identification of berbamine, oxyacanthine and rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: an in-silico studyView study →}, and bisBIQ alkaloids as a class have reported cytotoxic activity ^{2Reference 22002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}.

Gap: a computational prediction with zero wet-lab or in-vivo confirmation for oxyacanthine — the lowest tier of evidence ^{5Reference 52021Identification of berbamine, oxyacanthine and rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: an in-silico studyView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Adrenergic tone (sympatholytic)	vasodilation, blunted pressor response	cardiovascular (class-level)
Voltage-gated Ca²⁺ channel (bisBIQ class)	smooth-muscle relaxation, negative inotropy	antihypertensive (class-inferred, not measured for oxyacanthine)
Urease	inhibition (IC50 ~6.35 µg/mL in vitro)	antimicrobial-adjacent / H. pylori chemistry
General inflammatory mediators (oedema/complement)	modest suppression, weaker than berberine	anti-inflammatory

Only the urease inhibition and the weaker-than-berberine anti-inflammatory effect are directly measured for isolated oxyacanthine; the calcium-antagonist/sympatholytic mechanism is class-level pharmacology.

Pharmacokinetics

There are no dedicated pharmacokinetic studies for oxyacanthine. As a large, dimeric bisbenzylisoquinoline alkaloid it shares the class profile of poor aqueous solubility and low, variable oral bioavailability seen across bisBIQ alkaloids (tetrandrine, berbamine) ^{6Reference 62021Thirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicityView study →}, and barberry’s alkaloids in general show low oral absorption (berberine is the reference case) ^{1Reference 1Mokhber-Dezfuli N et al. · 2014Phytochemistry and pharmacology of Berberis speciesView study →}. Practically, any activity from whole-root barberry preparations is dominated by berberine, not oxyacanthine, and systemic exposure to isolated oxyacanthine from herbal use is assumed low — everything here is class-inference.

Clinical trials

There are no human trials of isolated oxyacanthine for any indication; all human relevance is indirect (whole barberry root/berberine), and the evidence base is a handful of in-vitro/in-silico isolate studies plus class reviews.

Last checked: July 2026.

Toxicity & Safety

Oxyacanthine carries a [low] flag — it is a minor co-alkaloid with essentially no isolated toxicology (the one relevant datum is minimal in-vitro cytotoxicity ^{3Reference 32018NMR, novel pharmacological and in-silico docking studies of oxyacanthine and tetrandrine: bisbenzylisoquinoline alkaloids from Berberis glaucocarpa rootsView study →}) and no human exposure data. It is deliberately set below its cousin tetrandrine ([moderate]), which has real clinical dosing and documented organ accumulation/metabolic activation — none of which is established for oxyacanthine. One honest caveat is kept in the text without escalating the flag: the bisbenzylisoquinoline class is cardioactive (calcium antagonism, negative inotropy) ^{2Reference 22002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}, so meaningful systemic exposure to concentrated oxyacanthine would carry theoretical cardiovascular/hypotensive potential. In practice, real-world exposure is via whole barberry root, where berberine’s own documented hazards (bilirubin-albumin displacement → kernicterus risk; CYP3A4/P-gp drug interactions) dominate the safety picture, not oxyacanthine.

Pregnancy & lactation

Avoid. Barberry root is traditionally cautioned/contraindicated in pregnancy — its principal alkaloid berberine displaces bilirubin from albumin (neonatal kernicterus risk), and bisBIQ alkaloids as a class carry reproductive/embryotoxicity concern — and there are no safety data for isolated oxyacanthine.

Dosage

There is no validated or recommended dose — oxyacanthine is not sold or used as an isolated supplement and has no human dosing precedent, occurring only as a minor fraction of barberry (Berberis) root/root-bark total alkaloids (~4% total, berberine-dominated).

References